Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. News
  7. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
Delayed Nasdaq Copenhagen  -  10:59 2022-12-07 am EST
888.90 DKK   -0.68%
05:25aNOVO NORDISK : Deutsche Bank reaffirms its Buy rating
MD
12/05Novo Nordisk A/S – Share repurchase programme
GL
12/05European Midday Briefing: Fed Fears Outweigh -2-
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novo Nordisk Says Phase 3a Trial of Once-Weekly Insulin Icodec Met Primary Endpoint

09/22/2022 | 06:12am EST


ę MT Newswires 2022
All news about NOVO NORDISK A/S
05:25aNOVO NORDISK : Deutsche Bank reaffirms its Buy rating
MD
12/05Novo Nordisk A/S – Share repurchase programme
GL
12/05European Midday Briefing: Fed Fears Outweigh -2-
DJ
12/05EMEA Morning Briefing: China Reopening Hopes May Boost Shares
DJ
12/03Amgen says experimental obesity drug has promising durability
RE
12/02MT Hoejgaard Wins DKK600 Million Contract to Build New Factory for Novo Nordisk
MT
12/02Rigel Pharmaceuticals Shares Leap Premarket on FDA OK of Rezlidhia
DJ
11/30Novo Nordisk A/S – Share repurchase programme
GL
11/30Novo Nordisk A/S – Share repurchase programme
GL
11/25NOVO NORDISK : Berenberg reaffirms its Neutral rating
MD
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Financials
Sales 2022 176 B 24 790 M 24 790 M
Net income 2022 55 185 M 7 784 M 7 784 M
Net Debt 2022 5 401 M 762 M 762 M
P/E ratio 2022 36,5x
Yield 2022 1,33%
Capitalization 2 008 B 283 B 283 B
EV / Sales 2022 11,5x
EV / Sales 2023 9,95x
Nbr of Employees 52 696
Free-Float 75,0%
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 24
Last Close Price 888,90 DKK
Average target price 878,75 DKK
Spread / Average Target -1,14%
EPS Revisions
Managers and Directors
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Henrik Ehlers Wulff Senior Vice President-Diabetes API
Stephen Gough Global Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVO NORDISK A/S21.77%285 921
JOHNSON & JOHNSON3.57%460 411
ELI LILLY AND COMPANY33.42%350 179
ABBVIE INC.22.16%289 437
PFIZER, INC.-15.82%279 038
MERCK & CO., INC.43.65%276 181